Transcend Therapeutics
Marty was previously Chief Development Officer and Director at Oncoceutics, which was acquired by Chimerix in Q1 2021. He brings 39 years of senior executive experience in the pharmaceutical industry, and has led research and development resulting in FDA approval of nine New Drug Applications, issuance of 39 US patents, and five major biopharma exits for $3.5B in combined value.
This person is not in any offices
Transcend Therapeutics
1 followers
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.